Levetiracetam in juvenile myoclonic epilepsy: Long-term efficacy in newly diagnosed adolescents

Alberto Verrotti, Caterina Cerminara, Giangennaro Coppola, Emilio Franzoni, Pasquale Parisi, Paola Iannetti, Paolo Aloisi, Elisabetta Tozzi, Raffaella Cusmai, Federico Vigevano, Francesco Chiarelli, Paolo Curatolo

Research output: Contribution to journalArticlepeer-review

Abstract

The aim of this study was to evaluate the efficacy and tolerability of levetiracetam (LEV) monotherapy in juvenile myoclonic epilepsy (JME). The study group consisted of 32 patients with epilepsy (20 males, 12 females) with a mean age of 13 years 3 months (SD 7y 11mo) at seizure onset. LEV was administered as the first drug; all patients were followed up at 6 and 12 months. The dose that achieved seizure control ranged from 1000 to 2500mg/daily. At 6-month evaluation: 15 patients were seizure free; 14 patients were responders (>50% reduction in seizures); and three patients had marginal effects (

Original languageEnglish
Pages (from-to)29-32
Number of pages4
JournalDevelopmental Medicine and Child Neurology
Volume50
Issue number1
DOIs
Publication statusPublished - Jan 2008

ASJC Scopus subject areas

  • Clinical Neurology
  • Pediatrics, Perinatology, and Child Health
  • Neuroscience(all)

Fingerprint

Dive into the research topics of 'Levetiracetam in juvenile myoclonic epilepsy: Long-term efficacy in newly diagnosed adolescents'. Together they form a unique fingerprint.

Cite this